Physician profile
Mark Petrovani
NPI 1871758565
$1,011.99
in general payments reported to CMS, 2019-2025
11 companies · $149 in 2025
The $149 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.77 · 2020: $350 · 2021: $354 · 2022: $29.05 · 2023: $63.54 · 2024: $43.66 · 2025: $149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $255.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $345.69 | 2020-2025 | Yeztugo |
| Lilly USA, LLC | $154.86 | 2020-2024 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $124.96 | 2021 | |
| Viiv Healthcare Company | $110.64 | 2020-2025 | Dovato |
| Organon LLC | $65.78 | 2023-2025 | Nexplanon |
| Glaxosmithkline, LLC. | $55.56 | 2023-2025 | Arexvy, Shingrix, Bexsero |
| Janssen Biotech, INC. | $45.78 | 2020-2021 | |
| Smith+Nephew, INC. | $40.77 | 2020-2025 | Collagenase Santyl |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $29.05 | 2022 | |
| Genentech USA, INC. | $22.77 | 2019 | |
| Abiomed | $16.13 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Petrovani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.